Sign in

You're signed outSign in or to get full access.

VP

Verrica Pharmaceuticals Inc. (VRCA)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 showed operational traction but mixed financials: total revenue was $0.344M, down 82.7% year over year, while net loss per share improved to $(0.24) from $(0.53) YoY as SG&A fell materially; sequential dispensed applicator units for YCANTH rose 12.3% to 8,654, indicating demand normalization despite revenue recognition lag tied to distributor inventory .
  • Positive surprise: management reported “positive quarterly revenue earlier than previously disclosed expectations,” reflecting new demand and orders from its primary distribution partner; distributor inventory levels were “normalized,” positioning revenue to better translate from demand in 2025 .
  • Cost actions taking hold: SG&A dropped to $10.0M in Q4 from $17.0M in Q4 2023 (−41%), and R&D fell to $1.2M from $5.3M (−78%), driven by restructuring and lower VP-315 clinical costs .
  • Balance sheet commentary: cash and cash equivalents were $46.3M at year-end; under GAAP, cash was not sufficient for 12 months absent inflows, but potential $8M Torii milestone on Phase 3 common warts or Series A warrant exercises (up to $25M) could extend runway; OrbiMed debt covenants were waived for Q4 2024 and Q1 2025 .
  • Pipeline catalysts: VP-315 Phase 2 post‑hoc analysis showed a 97% ORR; common warts Phase 3 could begin as early as mid‑2025 with Torii funding Verrica’s portion via future milestones/royalties, and YCANTH single applicator launched in Q1 2025 to expand access and reduce physician acquisition costs .

What Went Well and What Went Wrong

What Went Well

  • Sequential demand metrics improved: YCANTH dispensed applicator units increased 12.3% QoQ to 8,654, versus 7,706 in Q3 and 5,975 in Q2; management emphasized normalized distributor inventory and new single‑applicator availability to reduce practice acquisition costs and expand access .
  • Operating expense reductions: SG&A fell to $10.0M in Q4 (from $17.0M in Q4 2023), and R&D declined to $1.2M (from $5.3M); Q4 net loss narrowed to $(16.2)M vs $(24.6)M YoY, with non‑GAAP net loss per share improving to $(0.18) from $(0.48) YoY .
  • Pipeline momentum: VP‑315 Phase 2 analysis reported a 97% ORR and ~51% complete histologic clearance in Part 2 cohorts; management expects genomic/immune response data and end‑of‑Phase 2 meeting minutes in H1 2025 .

Quote: “Our goal is to generate cash positive monthly operating results by the end of 2025… With a leaner and more capital‑efficient operating model now in place, I believe 2025 is shaping up to become an important year for Verrica” .

What Went Wrong

  • Revenue recognition headwind: Q4 product revenue fell to $0.315M from $1.866M YoY as demand was largely met by existing distributor inventory; total revenue declined to $0.344M from $1.988M YoY .
  • Gross profit turned negative in Q4: total revenue of $0.344M vs combined cost of product and collaboration revenue of $0.625M yielded a calculated gross profit of $(0.281)M and a negative margin, reflecting inventory write‑offs and revenue mix .
  • Debt‑related non‑cash charges and leverage: change in fair value of derivative liability was $(2.648)M in Q4/FY, and interest expense rose materially for the year to $9.4M; failure to meet OrbiMed revenue threshold triggered principal repayments beginning in 2025 .

Financial Results

Headline P&L vs Prior Periods and Prior Year

MetricQ2 2024Q3 2024Q4 2024Q4 2023
Total Revenue ($USD Millions)$5.177 $(1.781) $0.344 $1.988
Net Loss ($USD Millions)$(17.186) $(22.860) $(16.202) $(24.614)
Net Loss per Share (GAAP)$(0.37) $(0.49) $(0.24) $(0.53)
Loss from Operations ($USD Millions)$(15.206) $(20.704) $(11.410) $(23.136)
SG&A ($USD Millions)$16.522 $16.083 $10.019 $16.994
R&D ($USD Millions)$3.319 $2.405 $1.168 $5.320
Interest Expense ($USD Millions)$2.368 $2.376 $2.349 $2.306

Revenue Type Breakdown

Revenue Type ($USD Millions)Q2 2024Q3 2024Q4 2024Q4 2023
Product Revenue (net)$4.892 $(1.865) $0.315 $1.866
Collaboration Revenue$0.285 $0.084 $0.029 $0.122
Total Revenue$5.177 $(1.781) $0.344 $1.988

Cost of Revenue and Calculated Gross Profit

MetricQ2 2024Q3 2024Q4 2024Q4 2023
Cost of Product Revenue ($USD Millions)$0.360 $0.351 $0.596 $0.145
Cost of Collaboration Revenue ($USD Millions)$0.182 $0.084 $0.029 $0.128
Gross Profit (calc.) ($USD Millions)$4.635 (5.177−0.360−0.182) $(2.216) (−1.781−0.351−0.084) $(0.281) (0.344−0.596−0.029) $1.715 (1.988−0.145−0.128)
Gross Margin (calc., %)89.5% N/A (negative) N/A (negative) 86.2%

KPIs

KPIQ2 2024Q3 2024Q4 2024
YCANTH Dispensed Applicator Units5,975 7,706 8,654
QoQ Growth (%)—+28.9% (7,706 vs 5,975) +12.3% (8,654 vs 7,706)

Non-GAAP

MetricQ4 2024Q4 2023
Non-GAAP Net Loss ($USD Millions)$(12.182) $(22.066)
Non-GAAP Net Loss per Share$(0.18) $(0.48)
Key AdjustmentsStock comp, non-cash interest, derivative change Stock comp, non-cash interest

Guidance Changes

Metric/TopicPeriodPrevious Guidance/CommentaryCurrent Guidance/CommentaryChange
YCANTH demand vs revenue timingQ4 2024/Q1 2025Most demand to be supported by existing distributor inventory into Q1 2025; no ex‑factory sales in Q3 Positive quarterly revenue earlier than expected as primary distribution partner ordered applicators in Q4; distributor inventory levels normalized Improved timing; earlier revenue recognition
YCANTH single applicatorQ1 2025Expected availability in Q1 2025 to reduce acquisition costs and expand access Became available in Q1 2025 Achieved
Common warts (VP-102) Phase 32025Initiation expected H1 2025; Torii funds Verrica’s portion via offsets; $8M milestone upon initiation in Japan Initiation could begin as early as mid‑2025; $8M milestone on initiation Maintained timing (refined to “mid‑2025”)
Operating expense (opex) profile2025Restructuring to cut opex ~50%; one‑time charge ~$1.0M Q4 SG&A reduced to $10.0M; continued lean operating model Achieved/maintained
Cash runway2024–2025As of 9/30/24, cash sufficient into Q1 2025 As of 12/31/24, GAAP cash not sufficient for 12 months, but Torii milestone ($8M) or Series A warrant exercises (up to $25M) could extend runway Lower baseline runway, potential extension via milestones/warrants
Debt covenants (OrbiMed)Q4 2024/Q1 2025—Waiver of going concern covenant for Q4 2024 and Q1 2025 Resolved covenant risk near term
Profitability targetYE 2025—Goal to be cash positive on a monthly operating basis by YE 2025 New target

Earnings Call Themes & Trends

TopicQ2 2024 (Prior Two Quarters)Q3 2024 (Prior Quarter)Q4 2024 (Current)Trend
Commercial realignment / cost actionsScaling commercial org; SG&A up with launch; J‑code in effect Restructuring; opex expected −50%; Jefferies engaged; negative net product revenue due to returns provision; inventory expected to support demand into Q1 2025 Leaner model; SG&A down; normalized distributor inventory; single applicator launched; improving sales productivity Improving execution, cost discipline
Demand and accessAdded specialty distributor; buy‑and‑bill and pharmacy channels developing Dispensed units 7,706; inventory to support demand; distributor mix adjustments Dispensed units 8,654; addition of local specialty pharmacies; easier access; pediatric expansion Sequential growth, broader access
Pipeline VP‑315 (BCC)Positive preliminary Phase 2 topline; safety/efficacy Continued data at conferences Post‑hoc analysis: 97% ORR; H1 2025 data + EOP2 minutes Strengthening data package; advancing regulatory path
Common warts (VP‑102)Amended Torii agreement; Phase 3 planned H1 2025; $8M milestone Continuing prep Phase 3 as early as mid‑2025; Torii funding structure reiterated On track
Debt/financingOrbiMed facility; interest expense rising with borrowings Exploring balance sheet options; engaged Jefferies $42M equity raise; covenant waivers; derivative liability change recognized Improved liquidity; managing debt mechanics

Management Commentary

  • “We completed our commercial strategy realignment, which generated promising sequential growth of dispensed applicator units of YCANTH while simultaneously implementing significant cost reductions across the organization.” (Jayson Rieger, CEO) .
  • “Based on achieving these early milestones, I believe Verrica is now on track to successfully execute our turnaround strategy… Our goal is to generate cash positive monthly operating results by the end of 2025.” (Jayson Rieger, CEO) .
  • “Gross product margins for the full year 2024 were 72%… Cost of product revenue of $1.9M included $0.9M of obsolete inventory costs.” (John Kirby, Interim CFO) .
  • “We believe that inventory has now reached a stable normalized level where demand for YCANTH applicator units will translate into new demand‑driven revenue regularly going forward into 2025.” (Management) .

Q&A Highlights

  • Demand and access: clinicians report improving access; single applicator is aiding buy‑and‑bill economics; management sees continued momentum into 2025 but maintains policy not to provide revenue guidance; one analyst referenced ~$15M 2025 consensus on the call, which management did not affirm .
  • Seasonality tailwinds: management prepared for potential uplift as warmer months increase pediatric activity; cautiously optimistic given deductible season and winter headwinds .
  • IP and competitive barriers: robust patent portfolio; prior settlement removed key 503B compounder presence; generics seen as a distant risk .
  • Channel/patient mix: dermatology remains majority, but pediatric adoption rising toward equilibrium mix (management cited possible 60/40 swings as rollout continues) .
  • VP‑315 timing and resourcing: remaining Phase 2 data and FDA feedback will drive Phase 3 path; current cost impact to advance near‑term steps viewed as de minimis; full rights retained .

Estimates Context

  • S&P Global consensus for Q4 2024 EPS and revenue was unavailable at time of analysis; attempted retrieval via S&P Global (Capital IQ) failed due to request limits. As a result, no formal beat/miss vs S&P Global consensus can be stated for Q4 2024 [SPGI retrieval error].
  • On the call, one analyst referenced 2025 sell‑side revenue consensus of ~$15M; management reiterated a policy not to provide revenue guidance and did not endorse the figure .

Key Takeaways for Investors

  • Near‑term revenue normalization should improve as distributor inventory resets and demand growth in dispensed units translates to new orders; watch Q1–Q2 2025 revenue progression vs Q4 demand narrative .
  • Cost controls are working: SG&A and R&D reductions materially narrowed quarterly losses; if demand builds while maintaining lean ops, monthly operating cash‑flow target by YE 2025 becomes more credible .
  • Pipeline catalysts in H1 2025: VP‑315 genomic/immune data and EOP2 minutes could re‑rate BCC opportunity; common warts Phase 3 initiation (with Torii funding and $8M milestone) adds value‑creating optionality without near‑term cash strain .
  • Balance sheet watch‑items: GAAP runway insufficient without inflows; monitor timing of Torii milestone and potential Series A warrant exercises; debt reclassification and derivative charges reflect heightened financing complexity under OrbiMed facility .
  • Commercial execution focus: single applicator launch, local specialty pharmacy adds flexibility; pediatric channel expansion and seasonality tailwinds could support growth in 2025 .
  • Trading implications: absent S&P consensus visibility, near‑term stock reaction likely tied to tangible revenue conversion from normalized inventory, quarterly unit trends, and pipeline updates; any early Phase 3 initiation signal or strong VP‑315 translational data could be meaningful catalysts .
  • Risks: inventory dynamics, returns reserves, debt service obligations, and non‑cash derivative valuation changes can drive P&L volatility; execution against turnaround milestones remains critical .

Appendix: Prior Quarter Snapshots

  • Q3 2024: total revenue $(1.781)M (negative due to returns provision), net loss $(22.860)M, EPS $(0.49); dispensed units 7,706; restructuring initiated to reduce opex by ~50% .
  • Q2 2024: total revenue $5.177M (net product $4.892M, including a one‑time stock‑in order), net loss $(17.186)M, EPS $(0.37); added specialty distributor and GPO partners; VP‑315 positive topline results announced .